Vivos Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.2M
- Price
- $0.1537
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.26%
- Volume
- 573.0K
About
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Quick stats
Shares outstanding33.6M
Computed float30.0M
Float / shares89.2%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001716166
Websitehttps://www.vivos.com
AI Summary
AI-generated1/24
standardbullishrestructuring
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
Vivos Therapeutics announced a restructuring and cost reduction plan expected to save an estimated $3.6 million annually beginning in Q4 2026, driven by staff reductions, vendor changes, and renegotiated contracts.
Revenue growth initiatives include roughly 3-fold referral growth at its Las Vegas Sleep and Airway Medicine Centers, an EEG diagnostic business projected at $1.5-$3.0 million annualized, an RPM program adding up to $3.5 million annualized by Q1 2027, and payer contract renegotiations worth an estimated $2.4-$5.6 million.
Management believes these efforts put the company on track to be cash flow positive by late 2026 or early 2027 and profitable in 2027, though all figures are forward-looking projections.
Red flags
- All savings and revenue figures are forward-looking estimates, not realized results
- Risk factors note potential need for additional financing and maintaining Nasdaq listing
- Staff reductions could carry severance costs or operational disruption